{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:02:55Z","timestamp":1791475375349,"version":"4.3.4"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,5,1]]},"DOI":"10.1093\/jnci\/djt026","type":"journal-article","created":{"date-parts":[[2013,2,20]],"date-time":"2013-02-20T22:21:48Z","timestamp":1361398908000},"page":"654-663","source":"Crossref","is-referenced-by-count":88,"title":["Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in\n          BOLERO-2"],"prefix":"10.1093","volume":"105","author":[{"given":"Michael","family":"Gnant","sequence":"first","affiliation":[{"name":"Affiliations of authors: Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria (MGn); Solid Tumor Breast Department, Memorial Sloan-Kettering Cancer Center, New York, NY (JB); Department of Medicine (Hematology\/Oncology), University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA (HSR); Department of Sur"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Baselga","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria (MGn); Solid Tumor Breast Department, Memorial Sloan-Kettering Cancer Center, New York, NY (JB); Department of Medicine (Hematology\/Oncology), University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA (HSR); Department of Sur"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope S.","family":"Rugo","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria (MGn); Solid Tumor Breast Department, Memorial Sloan-Kettering Cancer Center, New York, NY (JB); Department of Medicine (Hematology\/Oncology), University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA (HSR); Department of Sur"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinzaburo","family":"Noguchi","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria (MGn); Solid Tumor Breast Department, Memorial Sloan-Kettering Cancer Center, New York, NY (JB); Department of Medicine (Hematology\/Oncology), University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA (HSR); Department of Sur"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard A.","family":"Burris","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria (MGn); Solid Tumor Breast Department, Memorial Sloan-Kettering Cancer Center, New York, NY (JB); Department of Medicine (Hematology\/Oncology), University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA (HSR); Department of Sur"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Piccart","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria (MGn); Solid Tumor Breast Department, Memorial Sloan-Kettering Cancer Center, New York, NY (JB); Department of Medicine (Hematology\/Oncology), University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA (HSR); Department of Sur"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel N.","family":"Hortobagyi","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria (MGn); Solid Tumor Breast Department, Memorial Sloan-Kettering Cancer Center, New York, NY (JB); Department of Medicine (Hematology\/Oncology), University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA (HSR); Department of Sur"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Eakle","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria (MGn); Solid Tumor Breast Department, Memorial Sloan-Kettering Cancer Center, New York, NY (JB); Department of Medicine (Hematology\/Oncology), University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA (HSR); Department of Sur"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Mukai","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria (MGn); Solid Tumor Breast Department, Memorial Sloan-Kettering Cancer Center, New York, NY (JB); Department of Medicine (Hematology\/Oncology), University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA (HSR); Department of Sur"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroji","family":"Iwata","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria (MGn); Solid Tumor Breast Department, Memorial Sloan-Kettering Cancer Center, New York, NY (JB); Department of Medicine (Hematology\/Oncology), University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA (HSR); Department of Sur"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Geberth","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria (MGn); Solid Tumor Breast Department, Memorial Sloan-Kettering Cancer Center, New York, NY (JB); Department of Medicine (Hematology\/Oncology), University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA (HSR); Department of Sur"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lowell L.","family":"Hart","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria (MGn); Solid Tumor Breast Department, Memorial Sloan-Kettering Cancer Center, New York, NY (JB); Department of Medicine (Hematology\/Oncology), University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA (HSR); Department of Sur"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peyman","family":"Hadji","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria (MGn); Solid Tumor Breast Department, Memorial Sloan-Kettering Cancer Center, New York, NY (JB); Department of Medicine (Hematology\/Oncology), University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA (HSR); Department of Sur"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"El-Hashimy","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria (MGn); Solid Tumor Breast Department, Memorial Sloan-Kettering Cancer Center, New York, NY (JB); Department of Medicine (Hematology\/Oncology), University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA (HSR); Department of Sur"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shantha","family":"Rao","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria (MGn); Solid Tumor Breast Department, Memorial Sloan-Kettering Cancer Center, New York, NY (JB); Department of Medicine (Hematology\/Oncology), University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA (HSR); Department of Sur"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetiana","family":"Taran","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria (MGn); Solid Tumor Breast Department, Memorial Sloan-Kettering Cancer Center, New York, NY (JB); Department of Medicine (Hematology\/Oncology), University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA (HSR); Department of Sur"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Sahmoud","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria (MGn); Solid Tumor Breast Department, Memorial Sloan-Kettering Cancer Center, New York, NY (JB); Department of Medicine (Hematology\/Oncology), University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA (HSR); Department of Sur"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria (MGn); Solid Tumor Breast Department, Memorial Sloan-Kettering Cancer Center, New York, NY (JB); Department of Medicine (Hematology\/Oncology), University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA (HSR); Department of Sur"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Campone","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria (MGn); Solid Tumor Breast Department, Memorial Sloan-Kettering Cancer Center, New York, NY (JB); Department of Medicine (Hematology\/Oncology), University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA (HSR); Department of Sur"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen I.","family":"Pritchard","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria (MGn); Solid Tumor Breast Department, Memorial Sloan-Kettering Cancer Center, New York, NY (JB); Department of Medicine (Hematology\/Oncology), University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA (HSR); Department of Sur"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,2,19]]},"reference":[{"issue":"8","key":"2019050907092591300_CIT0001","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic\n            opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"2019050907092591300_CIT0002","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"2019050907092591300_CIT0003","volume-title":"Clinician\u2019s\n            Guide to Prevention and Treatment of Osteoporosis","author":"National Osteoporosis Foundation","year":"2010"},{"issue":"2","key":"2019050907092591300_CIT0004","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","article-title":"Skeletal effects of exemestane on bone-mineral density,\n            bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer\n            participating in the Intergroup Exemestane Study (IES): a randomised controlled\n            study","volume":"8","author":"Coleman","year":"2007","journal-title":"Lancet Oncol"},{"issue":"4","key":"2019050907092591300_CIT0005","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/bcr1757","article-title":"Effects of steroidal and nonsteroidal aromatase inhibitors\n            on markers of bone turnover in healthy postmenopausal women","volume":"9","author":"Goss","year":"2007","journal-title":"Breast Cancer Res"},{"issue":"6","key":"2019050907092591300_CIT0006","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00432-010-0964-y","article-title":"The effect of exemestane and tamoxifen on bone health\n            within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of\n            the US, German, Netherlands, and Belgium sub-studies","volume":"137","author":"Hadji","year":"2011","journal-title":"J Cancer\n            Res Clin Oncol"},{"issue":"7","key":"2019050907092591300_CIT0007","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/annonc\/mdn762","article-title":"Effects of exemestane and tamoxifen on bone health within\n            the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German,\n            12-month, prospective, randomised substudy","volume":"20","author":"Hadji","year":"2009","journal-title":"Ann Oncol"},{"issue":"3","key":"2019050907092591300_CIT0008","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.breast.2009.03.003","article-title":"The effect of exemestane or tamoxifen on markers of bone\n            turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre\n            (TEAM) trial","volume":"18","author":"Hadji","year":"2009","journal-title":"Breast"},{"issue":"7","key":"2019050907092591300_CIT0009","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.2007.11.0726","article-title":"Effect of anastrozole on bone mineral density: 5-year\n            results from the Anastrozole, Tamoxifen, Alone or in Combination trial\n            18233230","volume":"26","author":"Eastell","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019050907092591300_CIT0010","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Adjuvant endocrine therapy plus zoledronic acid in\n            premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12\n            bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncol"},{"issue":"5","key":"2019050907092591300_CIT0011","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ejca.2010.11.024","article-title":"Zoledronic acid preserves bone mineral density in\n            premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final\n            results from CALGB trial 79809","volume":"47","author":"Shapiro","year":"2011","journal-title":"Eur J Cancer"},{"issue":"11","key":"2019050907092591300_CIT0012","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A randomized trial of exemestane after two to three years\n            of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"N Engl J Med"},{"issue":"9453","key":"2019050907092591300_CIT0013","first-page":"60","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in\n            Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast\n            cancer","volume":"365(","author":"Howell","year":"2005","journal-title":"Lancet"},{"issue":"26","key":"2019050907092591300_CIT0014","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","article-title":"A comparison of letrozole and tamoxifen in postmenopausal\n            women with early breast cancer","volume":"353","author":"Thurlimann","year":"2005","journal-title":"N Engl J Med"},{"issue":"11","key":"2019050907092591300_CIT0015","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1158\/1535-7163.MCT-07-0312","article-title":"Exemestane\u2019s 17-hydroxylated metabolite exerts biological\n            effects as an androgen","volume":"6","author":"Ariazi","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2019050907092591300_CIT0016","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1634\/theoncologist.9-2-126","article-title":"Aromatase inhibitors for breast cancer in postmenopausal\n            women","volume":"9","author":"Campos","year":"2004","journal-title":"Oncologist"},{"issue":"8","key":"2019050907092591300_CIT0017","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1634\/theoncologist.2008-0055","article-title":"Aromatase inhibitors: are there differences between\n            steroidal and nonsteroidal aromatase inhibitors and do they matter?","volume":"13","author":"Miller","year":"2008","journal-title":"Oncologist"},{"issue":"7","key":"2019050907092591300_CIT0018","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1200\/JCO.2001.19.7.2107","article-title":"Steroidal side effects of exemestane","volume":"19","author":"Nabholtz","year":"2001","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019050907092591300_CIT0019","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1200\/JCO.2000.18.7.1399","article-title":"Exemestane is superior to megestrol acetate after\n            tamoxifen failure in postmenopausal women with advanced breast cancer: results of a\n            phase III randomized double-blind trial. The Exemestane Study Group","volume":"18","author":"Kaufmann","year":"2000","journal-title":"J Clin Oncol"},{"issue":"9762","key":"2019050907092591300_CIT0020","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(10)62312-4","article-title":"Adjuvant tamoxifen and exemestane in early breast cancer\n            (TEAM): a randomised phase 3 trial","volume":"377","author":"van de Velde","year":"2011","journal-title":"Lancet"},{"issue":"5","key":"2019050907092591300_CIT0021","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc1362","article-title":"The TOR pathway: a target for cancer\n            therapy","volume":"4","author":"Bjornsti","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"2019050907092591300_CIT0022","author":"US Food and Drug Administration"},{"issue":"13","key":"2019050907092591300_CIT0023","doi-asserted-by":"crossref","first-page":"9817","DOI":"10.1074\/jbc.M010840200","article-title":"Phosphatidylinositol 3-kinase\/AKT-mediated activation of\n            estrogen receptor alpha: a new model for anti-estrogen resistance","volume":"276","author":"Campbell","year":"2001","journal-title":"J Biol Chem"},{"issue":"7","key":"2019050907092591300_CIT0024","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1172\/JCI41680","article-title":"Hyperactivation of phosphatidylinositol-3 kinase promotes\n            escape from hormone dependence in estrogen receptor-positive human breast\n            cancer","volume":"120","author":"Miller","year":"2010","journal-title":"J Clin Invest"},{"issue":"1\u20135","key":"2019050907092591300_CIT0025","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jsbmb.2005.04.025","article-title":"Adaptive hypersensitivity to estrogen: mechanisms and\n            clinical relevance to aromatase inhibitor therapy in breast cancer\n            treatment","volume":"95","author":"Santen","year":"2005","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"2","key":"2019050907092591300_CIT0026","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2325\/jbcs.13.137","article-title":"Activation of PI3K\/Akt signaling and hormone resistance in\n            breast cancer","volume":"13","author":"Tokunaga","year":"2006","journal-title":"Breast Cancer"},{"issue":"1\u20135","key":"2019050907092591300_CIT0027","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jsbmb.2007.05.008","article-title":"Mechanisms of acquired resistance to endocrine therapy in\n            hormone-dependent breast cancer cells","volume":"106","author":"Yue","year":"2007","journal-title":"J Steroid Biochem Mol\n            Biol"},{"issue":"13","key":"2019050907092591300_CIT0028","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.2174\/092986707780831159","article-title":"mTOR inhibitors (rapamycin and its derivatives) and\n            nitrogen containing bisphosphonates: bi-functional compounds for the treatment of bone\n            tumours","volume":"14","author":"Ory","year":"2007","journal-title":"Curr Med Chem"},{"issue":"10","key":"2019050907092591300_CIT0029","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/sj.cdd.4401285","article-title":"M-CSF, TNFalpha and RANK ligand promote osteoclast\n            survival by signaling through mTOR\/S6 kinase","volume":"10","author":"Glantschnig","year":"2003","journal-title":"Cell Death\n            Differ"},{"issue":"5","key":"2019050907092591300_CIT0030","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.bone.2004.07.013","article-title":"Everolimus suppresses cancellous bone loss, bone\n            resorption, and cathepsin K expression by osteoclasts","volume":"35","author":"Kneissel","year":"2004","journal-title":"Bone"},{"issue":"6","key":"2019050907092591300_CIT0031","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive\n            advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"2019050907092591300_CIT0032","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1158\/0008-5472.SABCS11-S3-7","article-title":"Everolimus for postmenopausal women with advanced breast\n            cancer: updated results of the BOLERO-2 phase III trial","volume":"71","author":"Hortobagyi","year":"2011","journal-title":"Cancer\n            Res"},{"key":"2019050907092591300_CIT0033","volume-title":"Final progression-free survival analysis of BOLERO-2: a phase III\n            trial of everolimus for postmenopausal women with advanced breast cancer (abstract\n            P6-04-02). In: 2012 CTRC-AACR San Antonio Breast Cancer Symposium; December\n          4\u20138","author":"Piccart","year":"2012"},{"key":"2019050907092591300_CIT0034","journal-title":"Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women\n            with Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are\n            Refractory to Letrozole or Anastrozole (BOLERO 2)"},{"issue":"3","key":"2019050907092591300_CIT0035","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in\n            solid tumors. European Organization for Research and Treatment of Cancer, National\n            Cancer Institute of the United States, National Cancer Institute of\n            Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"24","key":"2019050907092591300_CIT0036","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1200\/JCO.2007.12.9866","article-title":"Choice and interpretation of statistical tests used when\n            competing risks are present","volume":"26","author":"Dignam","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2 Pt\n            1","key":"2019050907092591300_CIT0037","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1158\/1078-0432.CCR-06-1210","article-title":"Cumulative incidence in competing risks data and competing\n            risks regression analysis","volume":"13","author":"Kim","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2019050907092591300_CIT0038","volume-title":"Afinitor (Everolimus) Prescribing Information","year":"2011"},{"issue":"24","key":"2019050907092591300_CIT0039","doi-asserted-by":"crossref","first-page":"10329","DOI":"10.1158\/0008-5472.CAN-10-0578","article-title":"Zoledronic acid potentiates mTOR inhibition and abolishes\n            the resistance of osteosarcoma cells to RAD001 (everolimus): pivotal role of the\n            prenylation process","volume":"70","author":"Moriceau","year":"2010","journal-title":"Cancer Res"},{"issue":"1","key":"2019050907092591300_CIT0040","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/ijc.24710","article-title":"Bisphosphonates suppress insulin-like growth factor\n            1-induced angiogenesis via the HIF-1alpha\/VEGF signaling pathways in human breast cancer\n            cells","volume":"126","author":"Tang","year":"2010","journal-title":"Int J Cancer"},{"issue":"22","key":"2019050907092591300_CIT0041","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1200\/JCO.2005.07.097","article-title":"Effects of exemestane administered for 2 years versus\n            placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with\n            surgically resected early breast cancer","volume":"23","author":"Lonning","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019050907092591300_CIT0042","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1538-7836.2011.04207.x","article-title":"Osteoprotegerin, a new actor in vasculogenesis, stimulates\n            endothelial colony-forming cells properties","volume":"9","author":"Benslimane-Ahmim","year":"2011","journal-title":"J Thromb\n            Haemost"},{"issue":"1","key":"2019050907092591300_CIT0043","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.bbrc.2009.04.084","article-title":"Down-regulation of mTOR leads to up-regulation of\n            osteoprotegerin in bone marrow cells","volume":"384","author":"Mogi","year":"2009","journal-title":"Biochem Biophys Res\n            Commun"},{"issue":"1","key":"2019050907092591300_CIT0044","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/jcb.22232","article-title":"Osteoprotegerin production by breast cancer cells is\n            suppressed by dexamethasone and confers resistance against TRAIL-induced\n            apoptosis","volume":"108","author":"Rachner","year":"2009","journal-title":"J Cell Biochem"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/105\/9\/654\/28573619\/djt026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T07:10:12Z","timestamp":1557385812000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/105\/9\/654\/986919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,19]]},"references-count":44,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2013,2,19]]},"published-print":{"date-parts":[[2013,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djt026","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717985476.793473982","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717985476.793473027","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717985476.793473614","asserted-by":"object"}]},"ISSN":["1460-2105","0027-8874"],"issn-type":[{"value":"1460-2105","type":"electronic"},{"value":"0027-8874","type":"print"}],"subject":[],"published-other":{"date-parts":[[2013,5,1]]},"published":{"date-parts":[[2013,2,19]]}}}